Erschienen in:
01.03.2021 | Vascular Biology (H. Pownall, Section Editor)
APOA1: a Protein with Multiple Therapeutic Functions
verfasst von:
Blake J. Cochran, Kwok-Leung Ong, Bikash Manandhar, Kerry-Anne Rye
Erschienen in:
Current Atherosclerosis Reports
|
Ausgabe 3/2021
Einloggen, um Zugang zu erhalten
Abstract
Purpose of the Review
Apolipoprotein (APO) A1, the main apolipoprotein of plasma high-density lipoproteins (HDLs), has several well documented cardioprotective functions. A number of additional potentially beneficial functions of APOA1 have recently been identified. This review is concerned with the therapeutic potential of all of these functions in multiple disease states.
Recent Findings
Knowledge of the beneficial functions of APOA1 in atherosclerosis, thrombosis, diabetes, cancer, and neurological disorders is increasing exponentially. These insights have led to the development of clinically relevant peptides and APOA1-containing, synthetic reconstituted HDL (rHDL) preparations that mimic the functions of full-length APOA1.
Summary
APOA1 is a multifunctional apolipoprotein that has therapeutic potential in several diseases. Translation of this knowledge into the clinic is likely to be dependent on the efficacy and bioavailability of small peptides and synthetic rHDL preparations that are currently under investigation, or in development.